BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorSchmid, P.
dc.contributor.authorSalvador Bofill, J.
dc.contributor.authorBermejo, B.
dc.contributor.authorPhillips, M.
dc.contributor.authorWheatley, D.
dc.contributor.authorNeus, F.
dc.contributor.authorSchem, C.
dc.contributor.authorStradella, A.
dc.contributor.authorMele, M.
dc.contributor.authorCortes Salgado, A.
dc.contributor.authorQuiroga, V.
dc.contributor.authorAnton Torres, A.
dc.contributor.authorLlombart Cussac, A.
dc.contributor.authorZamora, E.
dc.contributor.authorViale, G.
dc.contributor.authorKuemmel, S.
dc.contributor.authorPrendergast, A.
dc.contributor.authorMousa, K.
dc.contributor.authorGluz, O.
dc.contributor.authorCortes, J.
dc.contributor.authoraffiliation[Schmid, P.] Queen Mary Univ London, Barts ECMC, Barts Canc Inst, London, England
dc.contributor.authoraffiliation[Salvador Bofill, J.] Hosp Univ Virgen Valme, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Bermejo, B.] Hosp Clin Univ Valencia, Biomed Res Inst INCLIVA, CIBERONC ISCIII GEICAM, Breast Canc Grp, Valencia, Spain
dc.contributor.authoraffiliation[Phillips, M.] Barts Hosp NHS Trust, Med Oncol, London, England
dc.contributor.authoraffiliation[Wheatley, D.] Royal Cornwall Hosp NHS Trust, Med Oncol, Truro, England
dc.contributor.authoraffiliation[Neus, F.] Hosp Univ Son Espases, Med Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Schem, C.] Mammazentrum Hamburg, Oncol, Hamburg, Germany
dc.contributor.authoraffiliation[Stradella, A.] IDIBELL, Oncol, Catalan Inst Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Mele, M.] Hosp Univ St Joan Reus, Oncol, Tarragona, Spain
dc.contributor.authoraffiliation[Cortes Salgado, A.] Hosp Univ Ramon y Cajal, FEA Oncol Med, Secc Tumores Mama & Ginecol, Madrid, Spain
dc.contributor.authoraffiliation[Quiroga, V.] Catalan Inst Oncol, Dept Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Quiroga, V.] Badalona Appl Res Grp Oncol B ARGO Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Anton Torres, A.] Hosp Univ Miguel Servet, Med Oncol, Geicam Breast Canc Grp, Zaragoza, Spain
dc.contributor.authoraffiliation[Llombart Cussac, A.] Hosp Arnau Vilanova, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Zamora, E.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Viale, G.] Ist Europeo Oncol, Pathol, Milan, Italy
dc.contributor.authoraffiliation[Kuemmel, S.] Kliniken Essen Mitte Evang Huyssens Stiftung, Breast Unit, Essen, Germany
dc.contributor.authoraffiliation[Kuemmel, S.] West German Study Grp, Essen, Germany
dc.contributor.authoraffiliation[Prendergast, A.] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
dc.contributor.authoraffiliation[Mousa, K.] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
dc.contributor.authoraffiliation[Gluz, O.] West German Study Grp, Breast Ctr, Monchengladbach, Germany
dc.contributor.authoraffiliation[Gluz, O.] Ev Hosp Bethesda, Breast Ctr Niederrhein, Monchengladbach, Germany
dc.contributor.authoraffiliation[Gluz, O.] Univ Hosp Cologne, Cologne, Germany
dc.contributor.authoraffiliation[Cortes, J.] Int Breast Canc Ctr, Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Cortes, J.] Int Breast Canc Ctr, Oncol, Barcelona, Spain
dc.contributor.funderF. Hoffmann-La Roche Ltd.
dc.date.accessioned2025-01-07T15:28:06Z
dc.date.available2025-01-07T15:28:06Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.404
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.404
dc.identifier.urihttps://hdl.handle.net/10668/27174
dc.identifier.wosID700527700124
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de Valme
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS411-S412
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleBARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de Valme
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía